

TRANSITIONS

A NEWSLETTER FOR EQUITY HOLDERS OF TRT

Coming Soon Ultrasound for LithoGold®

TRT's Litho-Gold® system may soon be used with an Ultrasound ("US") option. An international ultrasound company specializing in US equipment for localization in radiation therapy is in the process of creating an US adjunct to our lithotripsy system.

This mobile US device is ideal for hospitals and surgery centers and has many attractive features such as sub-millimeter spatial accuracy, which is critical for accurate stone localization. The system also includes a mobile infrared camera for precision positioning.

The device is stand-alone, thus it can be used to perform lithotripsy as well other urologic procedures, such as bladder and prostate scans, etc.

The system is also highly versatile and can be used with or without a C-arm. When used in conjunction with a C-arm, stones are initially located with x-ray then US is utilized. For those desiring to eliminate exposure to ionizing radiation, the US device can be used solely for localization throughout the procedure.

This option will soon be commercially available. For more information on this product, please contact Robert Warlick, TRT Sales Manager, at 877-966-1315 x. 105 or rwarlick@trtllc.com.

Around the World

Italy


TRT, through its Italian distributor HMT Italy, attended CO.R.TE., an Italian Conference on wounds and tissue repair, in Rome March 4-6. The more than 1,400 participants included plastic surgeons, vascular surgeons, wound healing specialists and dermatologists. The conference featured two shockwave sessions and a DermaGold training course attended by 40+ physicians; this should further boost already strong sales in Italy.

Middle East

TRT's European subsidiary, MTS, along with its Middle East distribution partner, HMT Srl, attended

this year's Arab Health Medical Fair in Dubai, UAE January 25-28. Arab Health is the biggest medical fair in the Middle East, drawing some 55,000 physicians as well as exhibitors, suppliers and distributors from 145 countries.

On display were our Orthogold100™ for orthopedics and Dermagold100™ for wound care. As expected, products generated high interest and a slew of promising sales leads.



First Patent of the Year

TRT was awarded its first patent for 2010. The latest addition to TRT's Intellectual Property portfolio is a novel lens configuration patent for our Software® technology that further strengthens our position as the premier shockwave company and inventor of unfocused shockwaves.

We have a large number of patents pending awaiting prosecution, including:

- treatment of the pancreas to stimulate insulin production in diabetic patients;
- stem cell stimulation;
- treatment / pre-treatment for radiation or chemical exposure; and
- a new shock wave applicator for cardiovascular treatments.



Across the Nation

Southeastern Section AUA (SESAUA)

TRT exhibited its LithoGold® urology system at the SESAUA Annual Meeting in Miami in late March. The largest of the AUA Sections, the SESAUA has almost 2,100 Board-certified urologist members who practice, teach, and research in the southeastern US, Panama, Puerto Rico, and the U.S. Virgin Islands.

TRT met with numerous potential customers during the meeting, many of whom have scheduled or are in the process of scheduling LithoGold demonstrations.

Another VetGold™ Success Story

When veterinarian Dr. Michael Good wanted to know how well our VetGold™ performed, we let him see for himself.

One of his patients, a Weimaraner, was attacked by a coyote, which tore most of the skin off the dog's face. The large wound became septic and completely unresponsive to antibiotics. TRT treated the animal with our VetGold device and results were evident almost immediately. Five days after the first treatment the wound was 60% healed. A second treatment was performed, and 2 weeks later 80% of the wound was healed, including hair growth over the new skin tissue. The wound continues to show improvement and will soon be completely healed.

Now Dr. Good is not only a believer; he is also a VetGold owner.



Before VetGold™ Treatment After 14 days (2 Treatments)

Upcoming Meetings

ISMST

Please join TRT at the International Society for Medical Shockwave Treatment (ISMST) annual congress at the Hyatt Regency Chicago on June 24-26.



This is the largest world gathering of medical specialists with an interest in extracorporeal shockwave therapy.

This meeting is an opportunity to see new, innovative products and treatments not currently presented at other medical meetings within the USA. This unique, yearly gathering of orthopedic surgeons, podiatric surgeons and other medical specialists highlights pioneering technology for ESWT treatment of various conditions such as tendinopathies, sports injuries, bone, cartilage and wound healing, CRPS, AVN, non-unions and even cardiac conditions. More information about the meeting is available at www.ismst.com.

American Urological Association (AUA)



American Urological Association

TRT would also like to invite you to join us at the AUA Annual Meeting in San Francisco May 29 - June 3. This international conference is the largest meeting of urologic professionals in the world, drawing some 10,000 attendees each year.

TRT will be showcasing our new Ultrasound system for the LithoGold®. Please visit us in **Booth 3101** in the Exhibit Hall during any of the exhibit hours to view our line of urology products and to speak with our sales team. We look forward to seeing you there!

Tissue Regeneration Technologies, LLC
130 Arnold Mill Park, Woodstock, GA 30188
Tel: (770) 966-1315
Tdd: (877) 966-1315
Fax: (770) 592-8910
Web: www.trtllc.com



TRT
Tissue Regeneration Technologies

This newsletter is not an offer to sell or solicitation of an offer to buy TRT securities. Investment decisions should be based on the risks and disclosures presented in TRT's Confidential Memorandum. This newsletter contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements are only predictions and not guarantees of performance. You should not place undue reliance on any forward-looking statements.